tiprankstipranks
Trending News
More News >
Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
US Market
Advertisement

Aytu BioScience (AYTU) Earnings Dates, Call Summary & Reports

Compare
1,267 Followers

Earnings Data

Report Date
Nov 17, 2025
TBA (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
-0.19
Last Year’s EPS
-0.2
Same Quarter Last Year
Based on 3 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Sep 23, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call highlighted significant enthusiasm around the upcoming launch of ExuA and positive financial metrics like the third consecutive year of positive adjusted EBITDA. However, challenges such as a decline in gross margin and potential competition in the ADHD portfolio present concerns.
Company Guidance
During the Aytu BioPharma, Inc. fiscal 2025 call, guidance was provided highlighting key financial metrics and strategic initiatives. For fiscal year 2025, the company reported net revenue of $66.4 million, a slight increase compared to the previous year, and achieved its third consecutive year of positive adjusted EBITDA at $9.2 million. The company emphasized the upcoming launch of ExuA, an FDA-approved novel treatment for major depressive disorder, expected to significantly impact Aytu’s market position within the $22 billion U.S. market. ExuA, distinct due to its 5-HT1A receptor agonist mechanism, is anticipated to address unmet needs in the MDD market by minimizing sexual dysfunction and weight gain side effects common to SSRIs and SNRIs. Aytu's strategic focus includes leveraging its Aytu RxConnect platform for efficient market penetration and is preparing for ExuA’s commercial launch by the end of 2025. The company also highlighted its plans to optimize gross margins, particularly through improved ADHD product packaging and cost structures. Additionally, Aytu plans to invest approximately $10 million in launching ExuA in fiscal 2026, with expectations to ramp up commercial operations significantly in the subsequent quarters.
ExuA Launch Plans
Aytu BioPharma has announced the upcoming launch of ExuA, a novel first-in-class treatment for major depressive disorder (MDD), expected to significantly transform the company.
Positive Adjusted EBITDA
The company reported a positive adjusted EBITDA for the third consecutive year, reaching $9.2 million for fiscal 2025.
Pediatric Portfolio Growth
The pediatric portfolio showed growth, with net revenue increasing from $7.3 million to $8.8 million, reflecting the positive effect of the company's return to growth plan.
Successful Financing
Aytu BioPharma completed a successful at-the-market public offering, raising $16.6 million gross and just under $15 million net, led by healthcare-focused institutional investors.

Aytu BioScience (AYTU) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

AYTU Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 17, 2025
2026 (Q1)
-0.19 / -
-0.2
Sep 23, 2025
2025 (Q4)
-0.03 / -2.93
-0.82-257.32% (-2.11)
May 14, 2025
2025 (Q3)
-0.17 / 0.20
-0.52138.46% (+0.72)
Feb 12, 2025
2025 (Q2)
-0.28 / -0.28
-0.04-600.00% (-0.24)
Nov 13, 2024
2025 (Q1)
-0.34 / -0.20
-1.4886.49% (+1.28)
Sep 26, 2024
2024 (Q4)
-0.45 / -0.82
-0.59-38.98% (-0.23)
May 15, 2024
2024 (Q3)
-0.64 / -0.52
-1.9373.06% (+1.41)
Feb 14, 2024
2024 (Q2)
-0.25 / -0.04
-2.1598.14% (+2.11)
Nov 14, 2023
2024 (Q1)
-0.04 / -1.48
-1.2-23.33% (-0.28)
Sep 27, 2023
2023 (Q4)
-0.95 / -0.59
-9.893.98% (+9.21)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

AYTU Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Sep 23, 2025
$2.51$2.06-17.93%
May 14, 2025
$1.35$2.59+91.85%
Feb 12, 2025
$1.39$1.38-0.72%
Nov 13, 2024
$1.74$1.55-10.92%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Aytu BioScience Inc (AYTU) report earnings?
Aytu BioScience Inc (AYTU) is schdueled to report earning on Nov 17, 2025, TBA (Confirmed).
    What is Aytu BioScience Inc (AYTU) earnings time?
    Aytu BioScience Inc (AYTU) earnings time is at Nov 17, 2025, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is AYTU EPS forecast?
          AYTU EPS forecast for the fiscal quarter 2026 (Q1) is -0.19.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis